Neurological Biomarkers Market Report 2025

The neurological biomarkers market size has grown rapidly in recent years. It will grow from $10.7 billion in 2024 to $11.96 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to increasing prevalence of neurological disorders, aging population, drug development needs, increased funding for neurological research, personalized medicine.

The neurological biomarkers market size is expected to see rapid growth in the next few years. It will grow to $19.96 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to biomarkers for early detection, biosensors, wearable devices, global health initiatives, patient-centric approach. Major trends in the forecast period include technological innovation in imaging, rapid advances in omics technologies, integration of artificial intelligence (ai), real-world evidence in biomarker validation, advancements in diagnostic technologies, collaboration between industry and research institutions.

The anticipated rise in the prevalence of neurological diseases is poised to drive the growth of the neurological biomarker market. Neurological illnesses impact the brain, spinal cord, and the body's nervous system. In the case of neurodegenerative disorders such as Parkinson's disease, neurological biomarkers play a crucial role in providing early diagnoses through pathological, biochemical, and genetic testing. As of December 2022, the Parkinson's Foundation reported an increase in new diagnoses of Parkinson's disease, reaching 90,000 in 2022 compared to 60,000 per year in 2021. This surge underscores the role of neurological biomarkers in addressing the growing prevalence of neurological diseases.

The increasing incidence of schizophrenia is expected to contribute to the growth of the neurological biomarkers market. Schizophrenia, a severe mental health disorder, presents cognitive, emotional, and behavioral symptoms. Neurological biomarkers offer the potential for early detection, objective diagnostic measures, personalized treatment, reduced reliance on subjective assessments, and a deeper understanding of the disorder's neurobiological mechanisms. Globally, approximately 24 million people, or 1 in 300 individuals (0.32%), suffer from schizophrenia, with adults experiencing this at a rate of one in 222 (0.4%), as reported by the World Health Organization in January 2022. This prevalence underscores the significance of neurological biomarkers in addressing conditions such as schizophrenia.

Major companies are forging partnerships to enhance innovation and solidify their market positions. For instance, in July 2022, NeuroSense Therapeutics Ltd., an Israel-based company developing treatments for severe neurodegenerative diseases partnered with NeuraLight, an Israel-based company developing objective and sensitive biomarkers for neurological disorders. This collaboration is to identify oculometric indicators for Amyotrophic Lateral Sclerosis (ALS) through the application of AI (Artificial Intelligence) and ML (Machine Learning). The partnership, which comes after NeuraLight's $25 million Series A financing, is to enhance the discovery and application of ALS digital indicators in a parallel study. This will be the collaboration's first clinical trial. The partnership is centered on the application of oculometric digital indicators, which may allow for patient classification and boost clinical trial success rates. Such collaborations facilitate the advancement and commercialization of novel therapies by combining resources and expertise.

Major companies in the neurological biomarkers market are developing innovative products, including advanced biomarker blood tests. For instance, in July 2023, Quanterix Corporation, a US-based company that specializes in the development and commercialization of ultra-sensitive digital immunoassay platforms launched the LucentAD biomarker blood test. This test, analyzing p-Tau 181 levels, aids medical professionals in evaluating patients with cognitive symptoms indicative of Alzheimer's disease. The test is positioned as a diagnostic tool for adults undergoing assessment for Alzheimer's disease but is not intended for standalone screening or diagnosis, emphasizing the need for a comprehensive diagnostic approach.

In April 2024, GE HealthCare, a US-based medical technology firm, acquired MIM Software Inc. for an undisclosed amount. GE HealthCare aims to enhance precision care by integrating advanced imaging analytics and streamlining workflows, ultimately improving patient outcomes and clinician efficiency. This strategic move positions GE HealthCare to provide more personalized treatment solutions across various medical specialties. MIM Software Inc., also a US-based company, specializes in medical imaging software and offers advanced imaging solutions that improve the identification and analysis of neurological biomarkers, aiding in the more effective diagnosis and monitoring of neurological disorders.

Major companies operating in the neurological biomarkers market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.

North America was the largest region in the neurological biomarkers market in 2024. The regions covered in the neurological biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurological biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

A neurological biomarker is a substance that offers objective and quantifiable information regarding the presence, progression, or characteristics of a neurological disorder or condition. These biomarkers play a crucial role in clinical practice, particularly during drug development.

The main categories of neurological biomarkers include proteomics biomarkers, genomics biomarkers, metabolomics biomarkers, imaging biomarkers, and others. Proteomics biomarkers specifically involve proteins or patterns of proteins that can be identified and monitored by analyzing proteins in bodily fluids. These biomarkers find applications in various neurological conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, schizophrenia, depression, multiple sclerosis, and spinal muscular atrophy. They are utilized by hospital laboratories, clinical diagnostic centers, research organizations, and other relevant entities.

The neurological biomarkers research report is one of a series of new reports that provides neurological biomarkers market statistics, including the neurological biomarkers industry's global market size, regional shares, competitors with neurological biomarkers market share, detailed neurological biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the neurological biomarkers industry. This neurological biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurological biomarker market consists of sales of genetic testing kits, electroencephalography (EEG) devices, and biomarker assay kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.